AstraZeneca’s New CALQUENCE® Data in Mantle Cell Lymphoma (MCL)
Dr. Preetesh Jain, Assistant Professor, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, discusses new CALQUENCE® (acalabrutinib) data presented at ASH 2020 demonstrating long-term efficacy and tolerability at three years for patients with mantle cell lymphoma (MCL).
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Cancer. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Cancer and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Cancer?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Preetesh Jain MBBS, MD, DM, PhD is an Asst. Prof. in the Department of lymphoma and myeloma at University of Texas M.D. Anderson Cancer Ctr., Houston, TX USA. Dr. Jain has received his medical degree from India and completed at 3 year residency and 3 year medical oncology fellowship at Tata Memorial Hospital in Mumbai India. Dr. Jain moved to US in 2008, completed his PhD in molecular medicine at Feinstein Institute for medical research on IL-17 in CLL micro-environment. He then completed a 2 year clinical fellowship and leukemia Department at University of Texas M.D. Anderson Cancer Center. Then he repeated a 3 year residency in internal medicine at University of Texas Houston, then he repeated a three-year medical oncology fellowship in UT M.D. Anderson Cancer Center. He is focused on working in the field of Mantle cell lymphoma, focusing on high risk MCL, and developing newer clinical trials and translational research studies.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
